Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Abatacept (Orencia®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0114. 2014 Authors' conclusions Abatacept (Orencia®) is recommended as an option for use within NHS Wales in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older who have had an insufficient response to other disease-modifying anti-rheumatic drugs including at least one tumour necrosis factor inhibitor. This recommendation applies only in circumstances where the approved Wales Patients Access Scheme is utilised. Indexing Status Subject indexing assigned by CRD MeSH Antirheumatic Agents; Arthritis, Juvenile; Child; Humans; Immunoconjugates Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32014000448 Date abstract record published 11/03/2014 |